Clinical Trials Using Tisagenlecleucel

Clinical trials are research studies that involve people. The clinical trials on this list are studying Tisagenlecleucel. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-10 of 10
  • Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

    This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
    Location: 9 locations

  • Study of Tisagenlecleucel in Combination With Pembrolizumab in r / r Diffuse Large B-cell Lymphoma Patients

    A multi-center, open-label, phase Ib study to evaluate the safety and efficacy of the administration of tisagenlecleucel in combination with pembrolizumab in patients with r / r DLBCL who have received 2 or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy and having failed to or are not candidates for ASCT. The study will consist of 2 parts: dose timing selection part and expansion part.
    Location: 5 locations

  • Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

    This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
    Location: 6 locations

  • Genetically Modified T-Cells in Treating Patients With Advanced Non-Hodgkin's Lymphoma

    This phase I trial studies the side effects and the best dose of genetically modified T-cells in treating patients with advanced non-Hodgkin's lymphoma. Biological therapies, such as genetically modified T-cells may stimulate or suppress the immune system in different ways and stop cancer cells from growing.
    Location: 3 locations

  • Study of Tisagenlecleucel in Combination With Ibrutinib in r / r Diffuse Large B-cell Lymphoma Patients

    A multi-center, open-label, phase Ib study to evaluate the safety and tolerability of the administration of tisagenlecleucel in combination with ibrutinib in patients with r / r DLBCL who have received two or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy, and who have progressed after or are not candidates for ASCT.
    Location: 2 locations

  • CART-19 T Cells after Stem Cell Transplant in Treating Patients with High-Risk Multiple Myeloma

    This phase II trial studies how well anti-cluster of differentiation (CD)19 chimeric antigen receptor (CART-19)T cells work in treating patients with high-risk multiple myeloma after a stem cell transplant. White blood cells called T cells are taken from the patient and are modified or genetically changed. These cells are called CART-19 T cells and are designed to identify and kill a type of white blood cell called a B cell. B cells may help multiple myeloma cells grow. By eliminating B cells, CART-19 T cells may help control multiple myeloma in patents after a stem cell transplant.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • CART-19 Cells in Treating Patients With Chemotherapy Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

    This phase II clinical trial studies how well CD19CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes (CART-19 cells) work in treating patients with chemotherapy recurrent or refractory B cell non-Hodgkin lymphoma. This type of non-Hodgkin lymphoma involves a kind of white cell (or lymphocyte) called the B-cell. T-cells are modified through gene transfer using a type of virus called a lentiviral vector to deliver the genetic material called CART-19 into a patient's T-cells. These modified cells are called CART-19 T-cells. The CART-19 T-cells will be able to identify and possibly kill cancerous B-cells and may help the body build an effective immune response to kill cancer cells.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

    This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, efficacy will be assessed at Day 29, then every 3 months for the first year, every 6 months for the second year, then yearly until the end of the study. Safety will be assessed throughout the study. The study is expected to end in approximately 8 years after first patient first treatment (FPFT). A post-study long term follow-up for lentiviral vector safety will continue under a separate protocol per health authority guidelines.
    Location: 2 locations

  • Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

    The purpose of the study is to assess the efficacy and safety of tisagenlecleucel in children and adolescents with relapsed / refractory B-cell non-Hodgkin lymphoma (r / r B-NHL). For pediatric patients who have r / r B-NHL, survival rates are dismal, only ~20-50% subjects are alive at 2 years with overall response rate (ORR) of 20-30% after conventional salvage chemotherapy.
    Location: 3 locations

  • Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed / Refractory B-cell Precursor Acute Lymphoblastic Leukemia

    This trial aims to compare the benefits and risks of tisagenlecleucel to blinatumomab or inotuzumab in adult patients with relapsed or refractory ALL. This trial investigates tisagenlecleucel as an additional treatment option for this patient population with high unmet medical need.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia